You're browsing as a guest. Sign in to unlock all features.
DERM
Journey Medical Corporation·Drug Manufacturers - Specialty & Generic·US
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed prod...
1 Total1 External0 In-site
DERMJourney Medical Corporation
2025-12-03🏥 HealthcareLong
Externalby MainlyPharma · vic
Journey Medical Corporation
主要经营地
Scottsdale, Arizona
详细的生意模式
皮肤科处方药商业化：通过自有销售团队推广已获批/即将获批产品；利润取决于产品组合、专利期与推广效率
护城河
在细分皮肤科拥有渠道与医生覆盖；新产品若临床差异化显著可带来短期壁垒
估值水平
FCF/EV -5.3%；TEV/EBITDA -219.17；P/E -21.26
EV/Market Cap
1.00x
网络观点
✅Emrosi于2025-04上市，被称为20年来首个口服酒糟鼻药；III期显示优于既有疗法。🌟看点：处方放量与市占提升。
AI的观点
✅“单品放量”带来业绩弹性。⚠️商业化执行、竞争品类与支付方准入决定成败；财务指标显示盈利/FCF仍偏弱。🔎看：处方趋势（NRx/TRx）、毛利与营销费用杠杆、产品生命周期管理。
原文发布时间
2025-12-04